Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flashing light goggles could ease depression, early study hints

NCT ID NCT06922812

Symptom relief Sponsor: University of Sao Paulo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a wearable device that delivers intermittent white light at 60 Hz can safely help people with moderate to severe depression. Thirty adults on stable antidepressant medication will wear the goggles for 30 minutes daily over two weeks. The main goal is to check safety and tolerability, while also looking for any improvement in mood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intermittent white light stimulation via wearable goggles
What this could lead to
If successful, this could point toward a new, non-invasive, side-effect-free treatment option for depression.
What could go wrong
This is a very early, small, open-label pilot study with no placebo control. Results may not be reliable, and the treatment might not work in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years; * Current diagnosis of Major Depressive Disorder (MDD), confirmed by MINI; HDRS-17 score between 8 and 23 at baseline; * Stable antidepressant regimen for at least 6 weeks prior to enrollment; * Able and willing to provide informed consent. Exclusion Criteria: * Diagnosis of other psychiatric disorders (e.g., bipolar disorder, psychotic disorders, OCD, ADHD, personality disorders, dementia); * Substance or alcohol use disorders; * Severe suicidal ideation or psychotic symptoms; * HDRS-17 score \>28; * Neurological or severe medical conditions; * History of epilepsy, migraine, or photosensitivity; * Retinal disease or cataracts; * Regular use of anti-inflammatory medications or clopidogrel; * Any worsening of symptoms during the trial (e.g., psychosis, HDRS \>28, or suicidal ideation); * Participation in another clinical trial within the last 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD)

Contacts and locations

Locations

  • University of São Paulo

    São Paulo, São Paulo, 05403-010, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.